- Home
- THTX vs LPTX Comparison
THTX vs LPTX Comparison
Compare THTX & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THTX
- LPTX
- Stock Information
- Founded
- THTX 1993
- LPTX 2011
- Country
- THTX Canada
- LPTX United States
- Employees
- THTX N/A
- LPTX N/A
- Industry
- THTX Biotechnology: Pharmaceutical Preparations
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- THTX Health Care
- LPTX Health Care
- Exchange
- THTX Nasdaq
- LPTX Nasdaq
- Market Cap
- THTX 119.1M
- LPTX 119.6M
- IPO Year
- THTX N/A
- LPTX N/A
- Fundamental
- Price
- THTX $2.53
- LPTX $0.38
- Analyst Decision
- THTX Hold
- LPTX Buy
- Analyst Count
- THTX 1
- LPTX 2
- Target Price
- THTX N/A
- LPTX $8.00
- AVG Volume (30 Days)
- THTX 139.5K
- LPTX 321.1K
- Earning Date
- THTX 07-09-2025
- LPTX 08-11-2025
- Dividend Yield
- THTX N/A
- LPTX N/A
- EPS Growth
- THTX N/A
- LPTX N/A
- EPS
- THTX N/A
- LPTX N/A
- Revenue
- THTX $88,666,000.00
- LPTX N/A
- Revenue This Year
- THTX N/A
- LPTX N/A
- Revenue Next Year
- THTX $15.13
- LPTX N/A
- P/E Ratio
- THTX N/A
- LPTX N/A
- Revenue Growth
- THTX 13.52
- LPTX N/A
- 52 Week Low
- THTX $1.12
- LPTX $0.22
- 52 Week High
- THTX $3.13
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- THTX 49.00
- LPTX 46.09
- Support Level
- THTX $2.38
- LPTX $0.38
- Resistance Level
- THTX $2.68
- LPTX $0.44
- Average True Range (ATR)
- THTX 0.09
- LPTX 0.04
- MACD
- THTX -0.02
- LPTX -0.00
- Stochastic Oscillator
- THTX 51.72
- LPTX 22.52
About THTX Theratechnologies Inc.
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .